SCHEMBL6244243

SCHEMBL6244243

CC(C)(C)OC(=O)N[C@](O)(CCc1cccc(C(F)(F)F)c1)C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 1/20 0.46
GRM3 Q14832 1/20 0.46
KDM4E B2RXH2 2/20 0.45
TDP1 Q9NUW8 1/20 0.45
FFAR4 Q5NUL3 3/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
THRB P10828 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43
HDAC1 Q13547 1/20 0.42
HDAC8 Q9BY41 1/20 0.42
LMNA P02545 1/20 0.42
GAA P10253 1/20 0.42
MAPT P10636 1/20 0.42
SLC13A5 Q86YT5 1/20 0.42
ALOX5 P09917 1/20 0.41
TAAR1 Q96RJ0 1/20 0.41
FFAR1 O14842 2/20 0.41
NR4A2 P43354 1/20 0.40
PRKCA P17252 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6245825 0.86 CTSS (0.51) MEN1KMT2ALMNATAAR1
SCHEMBL9218191 0.84 CA12 (0.50) MAPT
SCHEMBL6342947 0.84 CA12 (0.50) MAPT
SCHEMBL8951255 0.84 CA12 (0.50) MAPT
SCHEMBL25400472 0.78 RXFP1 (0.49) MEN1KMT2ATHRBRXFP1LMNA
SCHEMBL28578165 0.77 CTSK (0.54)
SCHEMBL25054244 0.77 CTSK (0.54)
SCHEMBL30882486 0.77 CTSK (0.54)
SCHEMBL28929817 0.76 HDAC1 (0.51) KDM4ETDP1MEN1KMT2ARXFP1
SCHEMBL27925867 0.76 GRM2 (0.56) GRM2GRM3KDM4ETDP1FFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050124683-A1 HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis AGOURON PHARMACEUTICALS, INC. 2005-06-09 US disclosed
WO-2005026114-A1 HIV PROTEASE INHIBITORS, COMPOSITIONS CONTAINING THE SAME AND THEIR PHARMACEUTICAL USES PFIZER INC. (US) 2005-03-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124683-A1 HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis PEPD, SERPINB1, ACE GRM2 4735/4885GRM3 4170/4885KDM4E 1438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.